Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 5/20 | 0.53 |
| ▸ | BRD4 | O60885 | 4/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CNR2 | P34972 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL669552 | 0.90 | NPSR1 (0.48) | NPSR1POLBKDM1ACNR1ALDH1A1 | |
| SCHEMBL7217397 | 0.82 | L3MBTL1 (0.57) | NPSR1POLBCNR1ALDH1A1CNR2 | |
| SCHEMBL4539709 | 0.82 | ALDH1A1 (0.57) | CNR1ALDH1A1TSHRSMN1; SMN2CNR2 | |
| SCHEMBL23927917 | 0.81 | HTR7 (0.58) | NPSR1POLBKDM1ACNR1ALDH1A1 | |
| SCHEMBL670091 | 0.81 | MAPT (0.52) | CREBBPALDH1A1TSHRCNR2TP53 | |
| SCHEMBL9037988 | 0.79 | LMNA (0.58) | CREBBPPOLBCNR1ALDH1A1TSHR | |
| SCHEMBL2074257 | 0.77 | CNR1 (0.46) | NPSR1KDM1ACNR1ALDH1A1TSHR | |
| SCHEMBL16197697 | 0.77 | HTR2A (0.51) | NPSR1POLBKDM1AALDH1A1TSHR | |
| SCHEMBL31121588 | 0.76 | KDM4E (0.64) | ALDH1A1SMN1; SMN2CNR2TDP1 | |
| SCHEMBL11682381 | 0.76 | KDM4E (0.64) | ALDH1A1SMN1; SMN2CNR2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9034895-B2 | Composition and methods for treating glioblastoma | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2015-05-19 | — | — | US | disclosed |
| US-9034895-B2 | Composition and methods for treating glioblastoma | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2015-05-19 | — | — | US | disclosed |
| US-9034895-B2 | Composition and methods for treating glioblastoma | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2015-05-19 | — | — | US | disclosed |
| EP-2606032-B1 | COMPOSITION AND METHODS FOR TREATING GLIOBLASTOMAS | UNIV WASHINGTON CT COMMERCIALI (US) | 2015-01-07 | — | — | EP | disclosed |
| EP-2606032-B1 | COMPOSITION AND METHODS FOR TREATING GLIOBLASTOMAS | UNIV WASHINGTON CT COMMERCIALI (US) | 2015-01-07 | — | — | EP | disclosed |
| US-20130197026-A1 | COMPOSITION AND METHODS FOR TREATING GLIOBLASTOMA | Unversity of Washington Through its Center for Commercialization (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130197026-A1 | COMPOSITION AND METHODS FOR TREATING GLIOBLASTOMA | Unversity of Washington Through its Center for Commercialization (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130197026-A1 | COMPOSITION AND METHODS FOR TREATING GLIOBLASTOMA | Unversity of Washington Through its Center for Commercialization (US) | 2013-08-01 | — | — | US | disclosed |
| EP-2606032-A2 | COMPOSITION AND METHODS FOR TREATING GLIOBLASTOMA | University Of Washington Through Its Center For Commercialization (US) | 2013-06-26 | — | — | EP | disclosed |
| WO-2012024670-A2 | COMPOSITION AND METHODS FOR TREATING GLIOBLASTOMA | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2012-02-23 | — | — | WO | disclosed |
| WO-2012024670-A2 | COMPOSITION AND METHODS FOR TREATING GLIOBLASTOMA | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2012-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130197026-A1 | COMPOSITION AND METHODS FOR TREATING GLIOBLASTOMA | MGMT, NEFM, TP53 | CREBBP 309/4885BRD4 1845/4885NPSR1 4155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.